{"name":"Cytovia, Inc.","slug":"cytovia-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"histamine dihydrochloride and IL-2","genericName":"histamine dihydrochloride and IL-2","slug":"histamine-dihydrochloride-and-il-2","indication":"Metastatic melanoma","status":"marketed"}]}],"pipeline":[{"name":"histamine dihydrochloride and IL-2","genericName":"histamine dihydrochloride and IL-2","slug":"histamine-dihydrochloride-and-il-2","phase":"marketed","mechanism":"This combination therapy stimulates immune cells through histamine receptor signaling and IL-2-mediated T-cell activation to enhance anti-tumor immunity.","indications":["Metastatic melanoma","Renal cell carcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1IWGt0aHk5LV9Ra2l3Z2FqQXB5am1RODZZaVIydHJvM2ZMX2R6bFJ4R0VGWjAwU25CdkYzY1VocnAwcGpTcnJTNXhYVU9zanB6Sk5pbE9NVk1OMURLeHM3VEdkWGRlcnPSAWxBVV95cUxOV05WRWNUVmU1Zy1QRzNXQlBwQjlUb2xieU91ekx1SmNQcXEwQ2dxVkxtaThLd21uUzFiaE1pWEVZVVJ3dUQ1RjNTelpyb3hyLVlHa3ZyT3Y5c0ZTQUM2MFRaTFNEYkp2X2E0N3c?oc=5","date":"2026-03-05","type":"pipeline","source":"BioInformant","summary":"The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant","headline":"The Pipeline for iPSC-Derived Cell Therapeutics in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxOaWU2bFJHZXcwLXpacUtXQnI0VUFGOHdaUEdTYlI3WHZQU0w4RVhNOTdBWTFMQlhzS3NmYVdjYkFNbkgzbkl1MzAyM3dpUlZ6cm9Bb3lHNFhiLTNMWm52WkpCMlZVM2pvbnZEamJJVDhuTDh2eURjcFR1RlRlN3Y2dU1Fc2hfWDQydlZ0eUhKMG95czZPLTVFUFJwdzdhZVRzcnlrcWtSYjU3V0JQRmpkV0N3U3JDTXEzQVBjQkNpNmNtS1htWC1PMFNCV0hGTVI1cXJfQU9ETm1RZ2o1ck02QmVCa0VFQU1jWThSWVRLOGlBYl9tVmJFTmxobE1ZMTVUZm5NWGQ3dWhKdXc?oc=5","date":"2025-07-15","type":"pipeline","source":"PR Newswire","summary":"Immorta Bio, a Scientific Longevity Company, Appoints Pharmaceutical Industry Veteran Dr. Armin Rath as Chief Business Officer - PR Newswire","headline":"Immorta Bio, a Scientific Longevity Company, Appoints Pharmaceutical Industry Veteran Dr. Armin Rath as Chief Business O","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOWE1OZjRWekFFSzlqem9DcUduOWloUUc4bmJWQ3pBM2pYdUtiNEF2dFBITmFOU3FSQklNRjJSNEp4SWZFaG9ERXdJSWM1RTJYZXRITEprY0RQZk5zSV95N1pXZVVOc1kyMlhkdUgxT1VCd1NNSHlQY1ZmSWFlcExiVHV3MV9abE0?oc=5","date":"2025-01-27","type":"pipeline","source":"Pharma Voice","summary":"Natural killer cells, a rising alternative to CAR-T cell therapy - Pharma Voice","headline":"Natural killer cells, a rising alternative to CAR-T cell therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxPRXM1dmd4a1Ftb2M5U0ZPcjRpR0NWWHVuWGlNV2xTU2pXVUhlYzBObGJpdEo0M0ZFNHl2YVBkSWxmNlBpdXNfOWZjOG5hMk1Td2Vqb1lKUUVjZTh4U3ZUeEZGcmV4dURoZlBiZWxxVnZRamxwNHpFT3JQNTc1ZDNybGoxTmI1bXQ4enhVVGxlR3J1X0VPRF9jWVNNYlE4U1FUZnpiODVnTGlDNlROUG9yaVZEOENwTk55d0Znb2RKZ3lzTm5IM01DTFFGTFg0dGhGUjJXdzE2Wm9rNzFCam5kWnhDaXd0TnRjTWFKcng1dGp3VXp4WnAyZA?oc=5","date":"2022-06-07","type":"pipeline","source":"PR Newswire","summary":"Cytovia Therapeutics Appoints Luca Scavo as Chief Financial Officer and James Priour as Chief Product Officer - PR Newswire","headline":"Cytovia Therapeutics Appoints Luca Scavo as Chief Financial Officer and James Priour as Chief Product Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxONzBINkREMThxNHNfbk9XU2hjTUM1cWtWOHpYdEY1a1Y1WmZ0M0JoSTBqZnVzeEpUUFRiNFMzSkQtRE5COVltcWxqSkpXSHV5Y016M1Q2Vk11M2taNkdEeDdlSXgzbHQ5VzZvb014OXNUMmEzcXZDWDNtOHBZU1B4a2N1bDYxMlV3bGdmaTNvZzRPckJsQlZRTw?oc=5","date":"2022-04-27","type":"deal","source":"BioSpace","summary":"Cytovia Goes Public in SPAC Deal Amidst Slow Biotech IPO Environment - BioSpace","headline":"Cytovia Goes Public in SPAC Deal Amidst Slow Biotech IPO Environment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOYVJPNnVrMjZjWFFuY2xaTUFEUTdJNW9NRkJtWGh4RzFhS3hVTG9vMUFscjJRMnRNLWZNTnZtaGExUy01dGQ2ZXlzVllMempybnBDODJsTk9ybENYeU9nZVZOczk1N2lRM19TTURxa002R19jUHJ6bHRlY1Q5YmhldkdmV0FSZEF1NzVINDV4NzhUVU5ucThNZjMwLWxOeV9XdG5pbjgzbw?oc=5","date":"2022-04-27","type":"deal","source":"Fierce Biotech","summary":"Cytovia inks SPAC merger to get natural killer cells prospects into the clinic - Fierce Biotech","headline":"Cytovia inks SPAC merger to get natural killer cells prospects into the clinic","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2022-04-26","type":"pipeline","source":"PR Newswire","summary":"Isleworth Healthcare Acquisition Corp. and Cytovia Therapeutics Announce Agreement for Business Combination to Create Publicly Listed Company Focused on Empowering Natural Killer Cell Therapeutics to ","headline":"Isleworth Healthcare Acquisition Corp. and Cytovia Therapeutics Announce Agreement for Business Combination to Create Pu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPZ0J4bHNtanpzcTlyYWgteUdJaUktb09fY1pTYkhDcklPS1htWklVWVZwMllJRURwcUhvYjNBS1pQaFNJa2YyUzB5ZWN3aUItWW1sbV9EektLeVc2SE1HalkxX0lJWFJaVV9ET2ZzcHdnNEVjdUk2S2Ntb2JPS0NGU203eXdwSmRtam9mNmJwX2VGTzVWRWQzQmtnMWgtSkw2TUE0?oc=5","date":"2011-01-10","type":"pipeline","source":"CBS News","summary":"Genetics Squared Changes Name To Everist Genomics, Names New CEO - CBS News","headline":"Genetics Squared Changes Name To Everist Genomics, Names New CEO","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}